Search research articles
Contact Us
Filters
Showing results (101-110 of 125) with videos related to
Page
of 13
Sort By:
JMIR Medical Informatics
|
November 3, 2020
Identifying Ectopic Pregnancy in a Large Integrated Health Care Delivery System: Algorithm Validation
Darios Getahun, Jiaxiao M Shi, Malini Chandra, et al.
Annals of Internal Medicine
|
June 11, 2019
Comparison of Universal Versus Age-Restricted Screening of Colorectal Tumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry: A Cohort Study
Dan Li, Elizabeth Hoodfar, Sheng-Fang Jiang, et al.
Breast Cancer Research : BCR
|
August 20, 2025
Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer
Erika Hamilton, Timothy Pluard, Judy S Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 2019
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
Mark Robson, Kathryn J Ruddy, Seock-Ah Im, et al.
The Lancet. Oncology
|
May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Tanja Fehm, Francesco Cottone, Kyle Dunton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results
Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen, et al.
Lancet (London, England)
|
June 6, 2022
Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study
Susan D Reed, Xiaolei Zhou, Laura Ichikawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Peter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
The Lancet. Oncology
|
April 19, 2014
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice André, Ruth O'Regan, Mustafa Ozguroglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
Nicholas Turner, Cristina Saura, Philippe Aftimos, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 125) with videos related to
Sort By:
Page
of 13
JMIR Medical Informatics
|
November 3, 2020
Identifying Ectopic Pregnancy in a Large Integrated Health Care Delivery System: Algorithm Validation
Darios Getahun, Jiaxiao M Shi, Malini Chandra, et al.
Annals of Internal Medicine
|
June 11, 2019
Comparison of Universal Versus Age-Restricted Screening of Colorectal Tumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry: A Cohort Study
Dan Li, Elizabeth Hoodfar, Sheng-Fang Jiang, et al.
Breast Cancer Research : BCR
|
August 20, 2025
Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer
Erika Hamilton, Timothy Pluard, Judy S Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 2019
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
Mark Robson, Kathryn J Ruddy, Seock-Ah Im, et al.
The Lancet. Oncology
|
May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Tanja Fehm, Francesco Cottone, Kyle Dunton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results
Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen, et al.
Lancet (London, England)
|
June 6, 2022
Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study
Susan D Reed, Xiaolei Zhou, Laura Ichikawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Peter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
The Lancet. Oncology
|
April 19, 2014
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice André, Ruth O'Regan, Mustafa Ozguroglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
Nicholas Turner, Cristina Saura, Philippe Aftimos, et al.
Page
of 13